GRM5 and lip and oral cavity carcinoma: The In vitro assay demonstrated that the agonist of mGluR5 DHPG even at a high concentration (100 μM) did not induce a change in the viability or cell proliferation, but enhanced the migration and invasiveness of the HSC3 oral cancer cells.